Top

Published in:

28-03-2022 | Original Article

Analysis of factors associated with the development of myelofibrosis in polycythemia vera and essential thrombocythemia patients: a single-center experience

Authors: Pınar Tığlıoğlu, Murat Albayrak, Abdulkerim Yıldız, Mesut Tığlıoğlu, Buğra Sağlam, Merih Reis Aras, Fatma Yılmaz, Senem Maral, Hacer Berna Afacan Öztürk, Ümit Yavuz Malkan

Published in: Journal of Hematopathology | Issue 2/2022

Abstract

In some patients with chronic myeloproliferative neoplasms, myelofibrosis (MF) develops as natural evolution of the disease. The aim of this study was to analyze predictive factors that may cause MF in polycythemia vera (PV) and essential thrombocythemia (ET) patients. This retrospective study was conducted on PV and ET patients who attended our hospital between 2008 and 2019. The development of MF during follow-up was recorded, and comparisons were made of the patients who developed MF and those who did not develop MF. Evaluation was made of 126 ET and 105 PV patients. During follow-up period, MF had developed 5.7% of PV and 7.1% of ET patients. It was determined that JAK-2 mutant allele burden, lymphocyte count, vitaminB12 levels, and grade of bone marrow fibrosis at diagnosis had statistically significant impact on the development of MF in all patients. In the logistic-regression analysis, it was found that initial hemoglobin, hematocrit, neutrophil-to-lymphocyte ratio, and monocyte count for PV patients; vitaminB12, the presence of splenomegaly; and BM fibrosis at diagnosis for ET patients have statistically significant effect on MF development. The results of the current study demonstrated that some parameters especially vitamin B12 levels can be used as predictive markers for the development of MF.

Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood J Am Soc Hematol 110(4):1092–1097

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405CrossRefPubMed

Cervantes F, Pereira A (2012) Prognostication in primary myelofibrosis. Curr Hematol Malig Rep 7(1):43–49. https://doi.org/10.1007/s11899-011-0102-1CrossRefPubMed

Tefferi A (2003) The forgotten myeloproliferative disorder: myeloid metaplasia. Oncologist 8(3):225–231CrossRefPubMed

Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22(2):437–438. https://doi.org/10.1038/sj.leu.2404914CrossRefPubMed

Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D et al (2008) Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 93(11):1645–1651. https://doi.org/10.3324/haematol.13346CrossRefPubMed

Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M et al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117(10):755–761. https://doi.org/10.1016/j.amjmed.2004.06.032CrossRefPubMed

Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L et al (2014) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124(16):2507–2513. https://doi.org/10.1182/blood-2014-05-579136 (quiz 615)CrossRefPubMedPubMedCentral

Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S et al (2007) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer 109(1):68–76. https://doi.org/10.1002/cncr.22365CrossRefPubMed

10.

Boiocchi L, Mathew S, Gianelli U, Iurlo A, Radice T, Barouk-Fox S, et al. Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage. Modern Pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2013;26(12):1577–85. https://doi.org/10.1038/modpathol.2013.109.

11.

Tefferi A, Thiele J, Vardiman JW (2009) The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 115(17):3842–3847. https://doi.org/10.1002/cncr.24440CrossRefPubMed

12.

Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29(6):761CrossRefPubMedPubMedCentral

13.

Barosi G (1999) Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol: Official J Am Soc Clin Oncol 17(9):2954–2970. https://doi.org/10.1200/jco.1999.17.9.2954CrossRef

14.

Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 81(2):159–166. https://doi.org/10.4065/81.2.159CrossRefPubMed

15.

Cervantes F, Alvarez-Larrán A, Talarn C, Gómez M, Montserrat E (2002) Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 118(3):786–790. https://doi.org/10.1046/j.1365-2141.2002.03688.xCrossRefPubMed

16.

Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E et al (2008) A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 111(7):3383–3387. https://doi.org/10.1182/blood-2007-11-121434CrossRefPubMed

17.

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379–2390. https://doi.org/10.1056/NEJMoa1311347CrossRefPubMed

18.

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391–2405. https://doi.org/10.1056/NEJMoa1312542CrossRefPubMedPubMedCentral

19.

Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L et al (2010) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24(9):1574–1579. https://doi.org/10.1038/leu.2010.148CrossRefPubMed

20.

Spivak JL (2017) Myeloproliferative neoplasms. N Engl J Med 376(22):2168–2181. https://doi.org/10.1056/NEJMra1406186CrossRefPubMed

21.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML et al (2012) Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 119(10):2239–2241. https://doi.org/10.1182/blood-2011-11-393819CrossRefPubMed

22.

Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol: Official J Am Soc Clin Oncol 23(10):2224–2232. https://doi.org/10.1200/jco.2005.07.062CrossRef

23.

Mercan R, Bitik B, Tufan A, Bozbulut UB, Atas N, Ozturk MA et al (2016) The association between neutrophil/lymphocyte ratio and disease activity in rheumatoid arthritis and ankylosing spondylitis. J Clin Lab Anal 30(5):597–601. https://doi.org/10.1002/jcla.21908CrossRefPubMed

24.

Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107(4):695–699. https://doi.org/10.1038/bjc.2012.292CrossRefPubMedPubMedCentral

25.

Romano A, Palandri F, Masarova L, Bonifacio M, Polverelli N, Elli EM et al (2018) Prognostic role of neutrophil to lymphocyte ratio (NLR) in myelofibrosis patients treated with ruxolitinib: a multi-center experience. Blood 132(Supplenent 1):4303. https://doi.org/10.1182/blood-2018-99-116418CrossRef

26.

Kisseleva T, Brenner DA (2008) Mechanisms of fibrogenesis. Exp Biol Med 233(2):109–122CrossRef

27.

Wong KL, Yeap WH, Tai JJ, Ong SM, Dang TM, Wong SC (2012) The three human monocyte subsets: implications for health and disease. Immunol Res 53(1–3):41–57. https://doi.org/10.1007/s12026-012-8297-3CrossRefPubMed

28.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M et al (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol: Official J Am Soc Clin Oncol 29(23):3179–3184. https://doi.org/10.1200/jco.2010.34.5298CrossRef

29.

Vener C, Novembrino C, Catena FB, Fracchiolla NS, Gianelli U, Savi F et al (2010) Oxidative stress is increased in primary and post-polycythemia vera myelofibrosis. Exp Hematol 38(11):1058–1065. https://doi.org/10.1016/j.exphem.2010.07.005CrossRefPubMed

30.

Gaman AM, Moisa C, Diaconu CC, Gaman MA (2019) Crosstalk between oxidative stress, chronic inflammation and disease progression in essential thrombocythemia. Rev Chim 70(10):3486–3489CrossRef

31.

Ellis JT, Peterson P, Geller SA, Rappaport H (1986) Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 23(2):144–155PubMed

32.

Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901. https://doi.org/10.1182/blood-2008-07-170449CrossRefPubMed

33.

Georgii A, Buhr T, Buesche G, Kreft A, Choritz H (1996) Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 22(sup1):15–29CrossRefPubMed

34.

Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F et al (2017) Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood J Am Soc Hematol 129(24):3227–3236

35.

Tefferi A (2013) Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 88(2):141–150CrossRefPubMed

36.

Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G et al (2009) Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol: Official J Am Soc Clin Oncol 27(18):2991–2999. https://doi.org/10.1200/jco.2008.20.3174CrossRef

37.

Cervantes F, Hernandez-Boluda JC, Villamor N, Serra A, Montserrat E (2000) Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. Eur J Haematol 65(2):104–108. https://doi.org/10.1034/j.1600-0609.2000.90262.xCrossRefPubMed

38.

Hernandez-Boluda JC, Pereira A, Gomez M, Boque C, Ferrer-Marin F, Raya JM et al (2014) The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. Haematologica 99(4):e55–e57. https://doi.org/10.3324/haematol.2013.101733CrossRefPubMedPubMedCentral

39.

Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T et al (2017) Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res 59:110–116. https://doi.org/10.1016/j.leukres.2017.06.001CrossRefPubMedPubMedCentral

40.

Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L et al (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30(8):1701–1707. https://doi.org/10.1038/leu.2016.148CrossRefPubMedPubMedCentral

41.

Cervantes F, Pereira A (2017) Does ruxolitinib prolong the survival of patients with myelofibrosis? Blood 129(7):832–837. https://doi.org/10.1182/blood-2016-11-731604CrossRefPubMed

Title: Analysis of factors associated with the development of myelofibrosis in polycythemia vera and essential thrombocythemia patients: a single-center experience
Authors: Pınar Tığlıoğlu
Murat Albayrak
Abdulkerim Yıldız
Mesut Tığlıoğlu
Buğra Sağlam
Merih Reis Aras
Fatma Yılmaz
Senem Maral
Hacer Berna Afacan Öztürk
Ümit Yavuz Malkan
Publication date: 28-03-2022
Publisher: Springer Berlin Heidelberg
Published in: Journal of Hematopathology / Issue 2/2022
Print ISSN: 1868-9256
Electronic ISSN: 1865-5785
DOI: https://doi.org/10.1007/s12308-022-00488-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Analysis of factors associated with the development of myelofibrosis in polycythemia vera and essential thrombocythemia patients: a single-center experience

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2022

Aleukemic T-lymphoblastic leukemia/lymphoma with massive cerebrospinal fluid infiltration

Non-Hodgkin lymphoma mimicking acute leukemia: a report of six cases and review of the literature

Protein kinase c delta expression in primary central nervous system lymphomas

Surface CD22 is a highly sensitive and specific B lineage marker and can replace cytoplasmic CD79a/cytoplasmic CD22 in flow cytometric reagent panels for the diagnosis of B-acute lymphoblastic leukemia

Rare presentation of B-lymphoblastic leukemia/lymphoma with intussusception in an adult

Correction to: What, how, and when for the WHO: will the clock be turned back for the next hematolymphoid tumor classification?